3 Likes
Response of the visit. This means a lot for the industry. Its perception definitely goes a notch up in eyes of world.
6 Likes
Indian pharma Industry outlook 2021 - An analytical Report by ICICI Securities with recommendation for Add, Buy, Hold & Reduce for different pharma stocks
6 Likes
Indian Pharma firms set to earn more revenue from USA - Get series of New ANDA approvals in recent months !
1 Like
https://www.youtube.com/watch?v=-Z1NNJ7x9O8
Pharma sector’s basic by Abhishek Singhal. Highly recommended. Thanks to both gentleman for such great educative session.
9 Likes
Indian Pharmaceutical Industry : Trends and Outlook:
6 Likes
Team wanted to understand if this risk of govt mandating doctors to prescribe only generic medicine names is being ignored and what effect it may have on the branded medicine sales, even for Indian Pharma firms…
I feel, profit growth rates could certainly come down if this does become a reality.
1 Like
In my view its a sane and wise thing to expect from any government, as the cost of Medicare is becoming expensive day by day the govt would certainly move to mandate the doctors to prescribe only generics. I think it’s not a question of if but when. Any govt want to keep the public happy by reducing prices where ever there is a chance.
Agree on your argument on socialist grounds to keep prices low should be the duty of the Govt.
But Govt will also need to ensure that quality does not dip. The regulator in India is not heard of. We all know FDA, but frankly i had to google to know who is the drug regulatory body for India… Its CDSO - https://cdsco.gov.in/opencms/opencms/en/Home/
So unless the govt strengthens this regulatory body, it might not be prudent to force doctors to prescribe only generic medicine names…
But it will not be easy! Look at the current state of affairs of other regulatory bodies in India, including the SEBI…
3 Likes
Please watch video in post #205. Everything is explained clearly
1 Like
As per post 204 by @Deven time- (1:28:00).
Custome Synthesis is like CRAMS. The company is helping the innovator company through various phases. They do not own IP, but they are helping the innovator company in the whole process. They are not doing it for their own molecule but they are service provider.
Another source thanks to @Rafi_Syed :
“Custom synthesis means the exclusive synthesis of compounds on behalf of the customer, i.e., you can order a specific molecule that is only synthesized on your request on the scale, with the purity and with the specification or methods you require”.
7 Likes
If we listen to pharma experts, many of them talk about China +1 strategy; wherein many customers are looking for India for their API supplies in addition to procuring their products from China.
However, Granules, Laurus Lab, Biocon and Divis are saying that they do not see business bombing because of China + 1 strategy. Having said that all of them are doing massive expansion of their capacities.
My questions : Which companies are openly saying that they are benefiting China +1 strategy Or China + 1 is a media term created by Analyst to convince an investor of the potential?
1 Like
No company will take china’s name openly. They all get materials from China and china will not hesitate to make life extremely difficult for these companies if they feel aggrieved by Companies touting China+1 or any variant of the same.
Another reason is that,for regulated markets, getting approvals for new sources of APIs take 1 to 2 yrs. Hence this china +1 effect will likely play out over next 2 -3 years. Dr. Chava even mentioned this in his ET interview.
2 Likes
This marks the third time in the last three months the authority has expressed concern over increasing approvals to fixed dose combination (FDC) medicines or drug cocktails in India.
In December, the authority had said a number of public grievances are on the “irrational pack size wherein a consumer is forced to buy more than his/her need”.
2 Likes
share resource it is bit old but relevant must study
1} https://www.ibef.org/download/Pharmaceuticals-November-2020.pdf
2 Likes
1 Like
Quite a few myths are challenged by covid, including duration to develop vaccine. There was a widespread belied that it takes decade to develop vaccine, but covid has proven that it can be done within year. This augar well for pharma companies as they will accelerate research/development for in some area IMO.
3 Likes